Parexel, a provider of solutions to accelerate the development and delivery of innovative new therapies to improve world health, from Clinical through Commercialization, has announced the opening of a new collaboration hub location within the Cambridge Innovation Center (CIC) in Cambridge, Mass. The new space will provide an ideal location for connection and collaboration with customers and employees working in Cambridge and Kendall Square.
“Cambridge is truly a hub for the life sciences industry,” said James Anthony, Senior Vice President and Global Head, Parexel Biotech. “With the continued growth of Parexel Biotech, we are seeing demand for our employees and customers to be in this area on a regular basis. The CIC presence provides us an opportunity to foster closer collaboration with our customers and provides our employees a convenient base of operations in this innovative and vibrant community.”
Parexel Biotech provides tailored solutions to the unique challenges faced by today’s biotech companies, from meeting clinical development timelines to optimizing product and pipeline value to navigating complex regulatory and reimbursement landscapes. The team provides life sciences companies strategic guidance based on years of industry experience combined with clinical and commercial services delivered through lean operational structures that are personalized to their needs and therapeutic specialty.
The Cambridge location will operate as a satellite location and will complement Parexel’s corporate headquarters, which is relocating to Newton, Mass. Earlier this month, Parexel convened the first meeting of its Patient Advisory Council, an initiative intended to drive innovation in drug development leveraging the patient perspective, in the Cambridge hub. Parexel announced the establishment of a second headquarters in its Durham, North Carolina location earlier this year.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.